The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC
Open accessAbstract
The VEGF pathway has been recognized as a key mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting VEGF and VEGF receptors have been developed and approved for use in NSCLCs. Preclinical studies have found that the VEGF and EGFR pathways share common downstream signaling, and these pathways can function exclusively of one another during oncogenesis. In EGFR-mutant NSCLCs, up-regulated EGFR signaling increases VEGF through hypoxia-independent mechanisms, and elevated VEGF, in turn, contributes to the emergence of resistance to EGFR tyrosine kinase inhibitors (TKIs). In clinical trials, the addition of anti-VEGF therapy to EGFR TKIs considerably improved clinical outcomes. In recently reported large randomized studies, the addition of bevacizumab or ramucirumab to EGFR TKIs substantially improved progression-free survival in patients with TKI-naive EGFR-mutant NSCLC. This article reviews the preclinical and clinical data supporting dual inhibition of EGFR and VEGF in EGFR-mutant NSCLC as a way to improve patient outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationEpidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC
Ramalingam, S. S., Vansteenkiste, J., Planchard, D., Cho, B. C., Gray, J. E., Ohe, Y., Zhou, C., Reungwetwattana, T., Cheng, Y., Chewaskulyong, B., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1913662 · Cited by 2,914
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Self-citationCross, D. A. E., Ashton, S. E., Ghiorghiu, S., Eberlein, C., Nebhan, C. A., Spitzler, P. J., Orme, J. P., Finlay, M. R. V., Ward, R. A., Mellor, M. J., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0337 · Cited by 2,246
AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411817 · Cited by 2,116
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Self-citationGoel, H. L., & Mercurio, A. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3627 · Cited by 1,253
Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici, C. S., Boşca, A. B., Șușman, S., Mărginean, M. V., Mihu, C., Istrate, M., Moldovan, I. M., Roman, A. L., & Mihu, C. M. (2018) · PubMed · Cited by 1,146
Midha, A., Dearden, S. P., & McCormack, R. (2015) · Europe PMC (PubMed Central) · Cited by 1,050
Ten years of anti-vascular endothelial growth factor therapy
Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,030
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Reck, M., Kaiser, R., Mellemgaard, A., Douillard, J.-Y., Orlov, S., Krzakowski, M., von Pawel, J., Gottfried, M., Bondarenko, I., Liao, M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70586-2 · Cited by 951
Self-citationSeto, T., Kato, T., Nishio, M., Goto, K., Atagi, S., Hosomi, Y., Yamamoto, N., Hida, T., Maemondo, M., Nakagawa, K., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70381-x · Cited by 750
Self-citationCiardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643
Saito, H., Fukuhara, T., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., Yoshimori, K., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30035-x · Cited by 615
Nakagawa, K., Garon, E. B., Seto, T., Nishio, M., Ponce Aix, S., Paz-Ares, L., Chiu, C.-H., Park, K., Novello, S., Nadal, E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30634-5 · Cited by 603
Self-citationSpratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., Leong, S., O'Bryant, C., Chow, L. Q. M., Serkova, N. J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.7537 · Cited by 549
Brain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E., Mahadevan, A., Floyd, S. R., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 534
The Role of VEGF and EGFR Inhibition: Implications for Combining Anti–VEGF and Anti–EGFR Agents
Tabernero, J. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0404 · Cited by 437
Herbst, R. S., Ansari, R., Bustin, F., Flynn, P., Hart, L., Otterson, G. A., Vlahovic, G., Soh, C.-H., O'Connor, P., & Hainsworth, J. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60545-x · Cited by 392
Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
Lin, J. J., Cardarella, S., Lydon, C. A., Dahlberg, S. E., Jackman, D. M., Jänne, P. A., & Johnson, B. E. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.103 · Cited by 356
Naumov, G. N., Nilsson, M. B., Cascone, T., Briggs, A., Straume, O., Akslen, L. A., Lifshits, E., Byers, L. A., Xu, L., Wu, H.-K., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2904 · Cited by 349
Self-citationVEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management
Izzedine, H., Massard, C., Spano, J. P., Goldwasser, F., Khayat, D., & Soria, J. C. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2009.11.001 · Cited by 332
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy474 · Cited by 321
Self-citationTargeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis
Larsen, A. K., Ouaret, D., El Ouadrani, K., & Petitprez, A. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.03.012 · Cited by 267
Vascular Endothelial Growth Factor Activates PI3K/Akt/Forkhead Signaling in Endothelial Cells
Abid, M. R., Guo, S., Minami, T., Spokes, K. C., Ueki, K., Skurk, C., Walsh, K., & Aird, W. C. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000110502.10593.06 · Cited by 248
Bancroft, C. C., Chen, Z., Yeh, J., Sunwoo, J. B., Yeh, N. T., Jackson, S., Jackson, C., & Van Waes, C. (2002) · International Journal of Cancer · doi:10.1002/ijc.10398 · Cited by 230
VEGF Inhibition, Hypertension, and Renal Toxicity
Hayman, S. R., Leung, N., Grande, J. P., & Garovic, V. D. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0242-z · Cited by 230
Lymphatic endothelium: a new frontier of metastasis research
Karkkainen, M. J., Mäkinen, T., & Alitalo, K. (2002) · Nature Cell Biology · doi:10.1038/ncb0102-e2 · Cited by 226
Johnson, B. E., Kabbinavar, F., Fehrenbacher, L., Hainsworth, J., Kasubhai, S., Kressel, B., Lin, C.-Y., Marsland, T., Patel, T., Polikoff, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3983 · Cited by 209
Rosell, R., Dafni, U., Felip, E., Curioni-Fontecedro, A., Gautschi, O., Peters, S., Massutí, B., Palmero, R., Aix, S. P., Carcereny, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30129-7 · Cited by 182
Herbst, R. S., Heymach, J. V., O’Reilly, M. S., Onn, A., & Ryan, A. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.2.239 · Cited by 145
Self-citationSide effects of anti-angiogenic drugs
Elice, F., & Rodeghiero, F. (2012) · Thrombosis Research · doi:10.1016/s0049-3848(12)70016-6 · Cited by 142
Human small cell lung cancer cells express functional VEGF receptors, VEGFR-2 and VEGFR-3
Tanno, S., Ohsaki, Y., Nakanishi, K., Toyoshima, E., & Kikuchi, K. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.03.006 · Cited by 132
Stinchcombe, T. E., Janne, P. A., Wang, X., Bertino, E. M., Weiss, J. M., Bazhenova, L. A., Gu, L., Lau, C. J., Paweletz, C. P., Jaslowski, A. J., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1847 · Cited by 131
Ichihara, E., Hotta, K., Nogami, N., Kuyama, S., Kishino, D., Fujii, M., Kozuki, T., Tabata, M., Harada, D., Chikamori, K., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000434 · Cited by 109
Angiogenesis Inhibitors in NSCLC
Manzo, A., Montanino, A., Carillio, G., Costanzo, R., Sandomenico, C., Normanno, N., Piccirillo, M. C., Daniele, G., Perrone, F., Rocco, G., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102021 · Cited by 105
Xu, L., Nilsson, M. B., Saintigny, P., Cascone, T., Herynk, M. H., Du, Z., Nikolinakos, P. G., Yang, Y., Prudkin, L., Liu, D., et al. (2010) · Oncogene · doi:10.1038/onc.2010.16 · Cited by 98
Self-citationMacrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0647 · Cited by 97
Tyrosine Kinase Inhibitor-Induced Hypertension
Agarwal, M., Thareja, N., Benjamin, M., Akhondi, A., & Mitchell, G. D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0708-8 · Cited by 97
Cascone, T., Xu, L., Lin, H. Y., Liu, W., Tran, H. T., Liu, Y., Howells, K., Haddad, V., Hanrahan, E. O., Nilsson, M. B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3216 · Cited by 96
Self-citationByers, L. A., & Heymach, J. V. (2007) · Clinical Lung Cancer · doi:10.3816/clc.2007.s.006 · Cited by 89
Self-citationMasuda, C., Yanagisawa, M., Yorozu, K., Kurasawa, M., Furugaki, K., Ishikura, N., Iwai, T., Sugimoto, M., & Yamamoto, K. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4036 · Cited by 89
Hung, M., Chen, I., Lin, P.-Y., Lung, J.-H., Li, Y., Lin, Y., Yang, C., & Tsai, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.5287 · Cited by 88
HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer
Jackson, A. L., Zhou, B. R., & Kim, W. Y. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.511617 · Cited by 86
Yamamoto, N., Seto, T., Nishio, M., Goto, K., Okamoto, I., Yamanaka, T., Tanaka, M., Takahashi, K., Fukuoka, M., & Yamamoto, N. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9007 · Cited by 71
Goss, G. D., Shepherd, F. A., Laurie, S. A., Gauthier, I. C., Leighl, N. B., Chen, E. X., Feld, R. D., Powers, J., & Seymour, L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.022 · Cited by 69
Strategies targeting angiogenesis in advanced non-small cell lung cancer
Wang, J., Chen, J., Guo, Y., Wang, B., & Chu, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17957 · Cited by 68
Scagliotti, G. V., & Govindan, R. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0225 · Cited by 61
Kato, T., Seto, T., Nishio, M., Goto, K., Yamamoto, N., Okamoto, I., Tao, L., Yu, W., Khaznadar, T., Tajima, K., et al. (2017) · Drug Safety · doi:10.1007/s40264-017-0596-0 · Cited by 60
Self-citationMaemondo, M., Fukuhara, T., Saito, H., Furuya, N., Watanabe, K., Sugawara, S., Iwasawa, S., Tsunezuka, Y., Yamaguchi, O., Okada, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9506 · Cited by 60
Zhou, Q. H., Wu, Y.-L. L. C., Cheng, Y., Li, Y., Chen, G.-Q., Cui, J., Yang, N., Song, Y., Li, X., Lü, S., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz260.002 · Cited by 55
Larkins, E. A., Scepura, B., Blumenthal, G. M., Bloomquist, E. W., Tang, S. W., Biable, M., Kluetz, P. G., Keegan, P., & Pazdur, R. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0221 · Cited by 49
Hata, A., Katakami, N., Kaji, R., Yokoyama, T., Kaneda, T., Tamiya, M., Inoue, T., Kimura, H., Yano, Y., Tamura, D., et al. (2018) · Cancer · doi:10.1002/cncr.31678 · Cited by 42
Gottfried, M., Bennouna, J., Bondarenko, I., Douillard, J., Heigener, D. F., Krzakowski, M. J., Mellemgaard, A., Novello, S., Орлов, С. В., Summers, Y., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0517-2 · Cited by 31
Self-citationYoh, K., Atagi, S., Reck, M., Garon, E. B., Ponce-Aix, S., Moro‐Sibilot, D., Winfree, K. B., Frimodt‐Moller, B., Zimmermann, A. H., Visseren‐Grul, C., et al. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1808781 · Cited by 18
Self-citation(2001) · PubMed
Cited by
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer Therapy
Patel, S. A., Nilsson, M. B., Le, X., Cascone, T., Jain, R. K., & Heymach, J. V. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1366 · Cited by 481
Self-citationFu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 397
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
Metadata
- Authors
- Le, X., Nilsson, M., Goldman, J., Reck, M., Nakagawa, K., Kato, T., Ares, L. P., Frimodt-Moller, B., Wolff, K., Visseren-Grul, C., Heymach, J. V., & Garon, E. B.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 16
- Issue
- 2
- Pages
- 205-215
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3094019790
- Cited by
- 339
- References
- 66
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.